Eric Sagonowsky

One year into his tumultuous tenure as the FDA's commissioner, Marty Makary, M.D., has laid out ambitious internal goals and a perhaps more ambitious

The wait is over. Fierce Biotech has released its annual ranking of the top 10 pharma R&D budgets of 2025—offering a clear look at which companies

Despite encountering a legal roadblock last month in his effort to rework the U.S. vaccine infrastructure, HHS secretary Robert F.

As artificial intelligence continues to rewrite the rules in countless industries, pharma companies are increasingly getting on board—with their AI tie-ups ranging from narrow projects to enterprise-wide initiatives.

Even as Eli Lilly gets underway with its next major obesity launch in Foundayo, an FDA document related to the oral treatment shows lingering reservations about multiple "unexpected serious" risks potentially related to the drug.

After a recent streak of buyouts by some of Big Pharma's serial acquirers, Belgium's UCB is getting in on the action with a Friday acquisition potentially worth more than $1 billion.

During Pfizer's right-sizing push after the COVID-19 pandemic, the company's multibillion-dollar cost-cutting campaign has affected its Ireland operations in several ways.

As Eli Lilly

There's no question Eli Lilly has been the most active biopharma dealmaker of recent months, but even the billions the pharma already spent on acquisitions hasn't exhausted its appetite.

Viridian Therapeutics has spent years moving its thyroid eye disease (TED) hopeful veligrotug through clinical trials and is now at the FDA's doorstep, with an approval decision expected next month.